Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Annika Deiß, Isabel Brecht, Axel Haarmann & Mathias Buttmann. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics 13:3, pages 313-335.
Read now
Read now
Articles from other publishers (20)
Zachary D. Crees, Michael P. Rettig & John F. DiPersio. (2023) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Therapeutic Advances in Hematology 14, pages 204062072311743.
Crossref
Crossref
Jan Kolcava, Monika Hulova, Lucie Rihova, Josef Bednarik & Pavel Stourac. (2020) The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab. Neurological Sciences 42:7, pages 2847-2853.
Crossref
Crossref
Johannis A. van Rossum, Zoé L.E. van Kempen, Louise Schilder, Birgit I. Lissenberg-Witte, Bernard Uitdehaag & Joep Killestein. (2019) Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders 36, pages 101382.
Crossref
Crossref
Michael Osherov & Ron Milo. 2019. Emerging Drugs and Targets for Multiple Sclerosis. Emerging Drugs and Targets for Multiple Sclerosis
134
169
.
Kazuki Yokokawa, Shin Hisahara, Yousuke Matsuura, Kazuna Ikeda, Emiko Tsuda, Masaki Saitoh, Kazuo Nakamichi, Masayuki Saijo, Yusuke Kamihara, Tsutomu Sato, Jun Kawamata & Shun Shimohama. (2016) Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. Journal of the Neurological Sciences 368, pages 304-306.
Crossref
Crossref
Teresa C. Frohman, Shin C. Beh, Eric J. Kildebeck, Ram Narayan, Katherine Treadaway & Elliot M. Frohman. (2016) Neurotherapeutic Strategies for Multiple Sclerosis. Neurologic Clinics 34:3, pages 483-523.
Crossref
Crossref
E Signoriello, R Lanzillo, V Brescia Morra, G Di Iorio, M Fratta, A Carotenuto & G Lus. (2015) Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Multiple Sclerosis Journal 22:7, pages 921-925.
Crossref
Crossref
Valeria Pietropaolo, Anna Bellizzi, Elena Anzivino, Marco Iannetta, Maria Antonella Zingaropoli, Donatella Maria Rodio, Manuela Morreale, Simona Pontecorvo, Ada Francia, Vincenzo Vullo, Anna Teresa Palamara & Maria Rosa Ciardi. (2015) Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment. Journal of NeuroVirology 21:6, pages 653-665.
Crossref
Crossref
Sinem Civriz Bozdag, Emre Tekgunduz & Fevzi Altuntas. (2015) The current status in hematopoietic stem cell mobilization. Journal of Clinical Apheresis 30:5, pages 273-280.
Crossref
Crossref
Claire BridelYan BeauverdKaveh SamiiPatrice H. Lalive. (2015) Hematologic modifications in natalizumab-treated multiple sclerosis patients. Neurology Neuroimmunology & Neuroinflammation 2:4.
Crossref
Crossref
Stephanie Shishido, Halvard Bönig & Yong-Mi Kim. (2014) Role of Integrin Alpha4 in Drug Resistance of Leukemia. Frontiers in Oncology 4.
Crossref
Crossref
Joseph R. Berger. 2014. Neurovirology. Neurovirology
357
376
.
María Chaparro. (2013) Novedades sobre los tratamientos para la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 36, pages 21-29.
Crossref
Crossref
Christian Wolf, Jagdev Sidhu, Christian Otoul, Dexter L. Morris, Jennifer Cnops, Jorg Taubel & Barbara Bennett. (2013) Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. PLoS ONE 8:3, pages e58438.
Crossref
Crossref
Silvia Rossi, Caterina Motta, Valeria Studer, Fabrizia Monteleone, Valentina De Chiara, Fabio Buttari, Francesca Barbieri, Giorgio Bernardi, Luca Battistini, Gary Cutter, Olaf Stüve, Marco Salvetti & Diego Centonze. (2012) A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Multiple Sclerosis Journal 19:1, pages 59-68.
Crossref
Crossref
Anna Bellizzi, Elena Anzivino, Donatella Maria Rodio, Anna Teresa Palamara, Lucia Nencioni & Valeria Pietropaolo. (2013) New Insights on Human Polyomavirus JC and Pathogenesis of Progressive Multifocal Leukoencephalopathy. Clinical and Developmental Immunology 2013, pages 1-17.
Crossref
Crossref
Devalingam Mahalingam & Tyler J. Curiel. 2013. Cancer Immunotherapy. Cancer Immunotherapy
335
376
.
Thomas F. Benkert, Lena Dietz, Elena M. Hartmann, Ellen Leich, Andreas Rosenwald, Edgar Serfling, Mathias Buttmann & Friederike Berberich-Siebelt. (2012) Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis. PLoS ONE 7:12, pages e52208.
Crossref
Crossref
A. Bellizzi, C. Nardis, E. Anzivino, D. M. Rodìo, D. Fioriti, M. Mischitelli, F. Chiarini & V. Pietropaolo. (2012) Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. Journal of NeuroVirology 18:1, pages 1-11.
Crossref
Crossref
Marek Mraz, Clive S. Zent, Amy K. Church, Diane F. Jelinek, Xiaosheng Wu, Sarka Pospisilova, Stephen M. Ansell, Anne J. Novak, Neil E. Kay, Thomas E. Witzig & Grzegorz S. Nowakowski. (2011) Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. British Journal of Haematology 155:1, pages 53-64.
Crossref
Crossref